The efficacy, safety, and beneficiary population of angiogenesis inhibitor apatinib plus chemotherapy in recurrent platinum-resistant ovarian cancer patients: A comparative cohort study.

Chunyan WuJiali YanYun Wu

Published in: The journal of obstetrics and gynaecology research (2024)

Angiogenesis inhibitor apatinib plus chemotherapy shows better treatment efficacy than chemotherapy alone with controllable safety profile in RPR-OC patients.

Keyphrases

locally advanced
end stage renal disease
endothelial cells
ejection fraction
newly diagnosed
vascular endothelial growth factor
peritoneal dialysis
chemotherapy induced
rectal cancer
wound healing
radiation therapy
replacement therapy
patient reported